Finn John, Pelham David, Walker Mary W, Gluchowski Charles
Synaptic Pharmaceutical Corporation, 215 College Road, Paramus, NJ 07952, USA.
Bioorg Med Chem Lett. 2002 Jul 8;12(13):1771-4. doi: 10.1016/s0960-894x(02)00288-3.
A series of sulfonamide neuropeptide Y Y5 antagonists was optimized by preparation of sets of analogues using high-throughput synthesis and purification techniques. Testing of these compounds for their ability to bind to the human NPY Y5 receptor revealed separate SAR trends for sulfonamide amides versus sulfonamide ureas versus sulfonamide amines. By understanding these SAR trends, potent compounds were identified in all three series.
